全膝关节置换术中氨甲环酸给药途径的贝叶斯网络荟萃分析与成本决策评价
该贝叶斯网络荟萃分析纳入40项随机对照试验,比较静脉、局部、口服、联合及无氨甲环酸(TXA)在初次全膝关节置换术中的效果。所有TXA途径均显著减少失血量、血红蛋白下降和输血风险,且不增加静脉血栓栓塞风险;联合方案疗效最佳,但口服TXA成本最低且最具成本效益,支持其作为常规 pragmatic 默认策略。
要点
- 所有TXA途径均减少失血和输血,不增加VTE风险。
- 联合方案疗效最佳,失血量减少400 mL。
- 口服TXA每人预期成本最低($129.43),最具成本效益。
核心结论
- 所有TXA给药途径均有效减少全膝关节置换术失血和输血且不增加VTE风险。
- 联合方案疗效最佳,但口服TXA在疗效、安全、成本和给药便利性间平衡最优,支持作为常规初次全膝关节置换术的实用默认策略。
研究设计与样本
- 贝叶斯网络荟萃分析,纳入40项随机对照试验,比较静脉、局部、口服、联合及无TXA。
- 构建决策分析成本模型,以输血为经济终点,纳入药物采购成本和输血相关住院成本。
主要发现
- 与无TXA相比,所有TXA途径显著减少总失血量、血红蛋白下降和输血风险。
- 联合方案失血量减少-400 mL(95%可信区间-512至-291),输血风险相对危险度0.251(95%可信区间0.117至0.468)。
- 口服、静脉和局部策略间差异不大。
- 各TXA途径均未观察到VTE风险增加。
- 口服TXA每人预期成本最低($129.43),其次为静脉($185.52)、局部($227.69)和联合($256.17);口服TXA在所有敏感性分析中均最具成本效益。
临床怎么用
- 口服TXA可作为常规初次全膝关节置换术的实用默认策略,兼顾疗效、安全、成本和给药便利性。
- 联合方案疗效最佳但成本较高,可根据患者出血风险和资源条件个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) is widely used in total knee arthroplasty (TKA) to reduce blood loss and transfusion; however, the optimal route of administration remains uncertain, particularly when considering both clinical outcomes and cost. METHODS: A Bayesian network meta-analysis of randomized controlled trials was performed comparing intravenous (IV), topical, oral, combined, and no TXA in TKA. The primary outcome was total blood loss. The secondary outcomes included hemoglobin (Hb) decrease, allogeneic transfusion, and venous thromboembolism (VTE). There were 40 randomized controlled trials included. A decision-analytic cost model was constructed using transfusion as the economic end point, incorporating drug acquisition costs and transfusion-related hospitalization costs. RESULTS: All TXA routes significantly reduced total blood loss, hemoglobin decline, and transfusion risk compared with no TXA. Combined regimens ranked highest for efficacy, demonstrating the greatest reduction in blood loss (-400 mL; 95% credible intervals -512 to -291) and transfusion risk (relative risk 0.251, 95% credible intervals 0.117 to 0.468). Differences among oral, IV, and topical strategies were modest. There was no increase in VTE risk observed across TXA routes. In cost analyses, oral TXA had the lowest expected per-patient cost ($129.43), followed by IV ($185.52), topical ($227.69), and combined ($256.17). Oral TXA remained the most cost-effective strategy across all sensitivity analyses. CONCLUSIONS: All TXA routes effectively reduce blood loss and transfusion in TKA without increased VTE risk. Although combined regimens demonstrate the greatest efficacy, oral TXA provides the most favorable balance of efficacy, safety, cost, and ease of administration, supporting its use as a pragmatic default strategy in routine primary TKA.
引用
- Hershfeld BE, Le JN, Xie K, et al. Optimal Route of Tranexamic Acid Administration in Total Knee Arthroplasty: A Bayesian Network Meta-Analysis with Decision-Analytic Cost Evaluation. J Arthroplasty. 2026. PMID: 42373027. doi:10.1016/j.arth.2026.06.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。